Free Trial

20 "Past Their Prime" Stocks to Dump From Your Portfolio - 20 of 20

 
 

Edgewise Therapeutics (NASDAQ:EWTX)

Edgewise Therapeutics logoEdgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. Read More 
 
Trailing Twelve Months EPS: ($1.50)
2025 EPS Estimate: ($1.45)
2026 EPS Estimate: ($1.79)

Current Stock Price
$28.30
Consensus Rating
Moderate Buy
Ratings Breakdown
6 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$41.29 (45.9% Upside)

More Investing Slideshows: